Urogen Pharma (NASDAQ:URGN) Shares Gap Up Following Strong Earnings

Urogen Pharma (NASDAQ:URGN)’s stock price gapped up prior to trading on Tuesday after the company announced better than expected quarterly earnings. The stock had previously closed at $19.02, but opened at $19.54. Urogen Pharma shares last traded at $19.1950, with a volume of 391,591 shares traded.

The company reported ($0.54) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.66) by $0.12. The business had revenue of $37.84 million during the quarter, compared to analyst estimates of $39.92 million.

Urogen Pharma News Roundup

Here are the key news stories impacting Urogen Pharma this week:

• Positive Sentiment: Q4 results: UroGen reported a narrower loss that beat estimates (reported EPS ≈ -$0.54 vs. -$0.66 expected), signaling improving profitability trends. Urogen Pharma (URGN) Reports Q4 Loss, Beats Revenue Estimates
• Positive Sentiment: Commercial progress: Management says the ZUSDURI launch is on-track, permanent J‑code reimbursement is effective Jan 1, 2026, and JELMYTO net sales grew to $94M in 2025 — points that support revenue upside and adoption. UroGen Announces ZUSDURI Launch is On-Track and Reports Fourth Quarter and Full Year 2025 Financial Results
• Positive Sentiment: Capital structure improvement: UroGen refinanced its term loan with Pharmakon Advisors at a lower fixed rate (8.25%) and extended amortization to 2030, and separately secured additional term financing — reducing near-term cash burn risk and cost of capital. UroGen Announces Refinanced Term Loan Agreement with Pharmakon Advisors
• Positive Sentiment: Sell-side support: A “buy” rating was reaffirmed with a $33 price target (implies meaningful upside from current levels), which could attract buyers over time. Benzinga coverage
• Neutral Sentiment: Management commentary and detail are available from the Q4 earnings call and multiple transcripts — useful for parsing guidance, adoption cadence for ZUSDURI, and commercial rollout timing. UroGen Pharma Ltd. Q4 2025 Earnings Call Transcript
• Negative Sentiment: Revenue slightly missed expectations: Q4 revenue of ~$37.8M versus consensus ~$39.9M — a modest miss that may temper near-term sentiment. UroGen (URGN) Q4 2025 Earnings Call Transcript (Yahoo)
• Negative Sentiment: Supply-chain/trade-risk disclosure: The company flagged reliance on a global supply chain for Jelmyto/Zusduri, warning trade tensions could hurt margins, pipeline and growth — a tangible risk to forecasts. Trade Tensions Put UroGen Pharma’s Margins, Pipeline and Growth at Risk

Analysts Set New Price Targets

Several research firms have issued reports on URGN. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Urogen Pharma in a report on Wednesday, January 21st. Wall Street Zen upgraded shares of Urogen Pharma from a “sell” rating to a “hold” rating in a research report on Saturday, November 8th. D. Boral Capital reaffirmed a “buy” rating and issued a $33.00 price target on shares of Urogen Pharma in a research note on Monday. Finally, Oppenheimer reiterated an “outperform” rating on shares of Urogen Pharma in a report on Monday. Six research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Urogen Pharma currently has a consensus rating of “Moderate Buy” and a consensus target price of $33.29.

Insider Activity

In other Urogen Pharma news, General Counsel Jason Drew Smith sold 7,479 shares of the stock in a transaction dated Tuesday, February 3rd. The shares were sold at an average price of $19.69, for a total value of $147,261.51. Following the completion of the sale, the general counsel owned 51,326 shares in the company, valued at approximately $1,010,608.94. This represents a 12.72% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Mark Schoenberg sold 7,373 shares of the business’s stock in a transaction that occurred on Tuesday, February 3rd. The stock was sold at an average price of $19.69, for a total value of $145,174.37. Following the transaction, the insider owned 144,985 shares in the company, valued at approximately $2,854,754.65. This represents a 4.84% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Company insiders own 4.70% of the company’s stock.

Institutional Investors Weigh In On Urogen Pharma

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Osaic Holdings Inc. boosted its stake in Urogen Pharma by 491.2% during the second quarter. Osaic Holdings Inc. now owns 3,695 shares of the company’s stock worth $50,000 after buying an additional 3,070 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. increased its stake in shares of Urogen Pharma by 27.2% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,275 shares of the company’s stock worth $53,000 after acquiring an additional 486 shares during the last quarter. State of Wyoming purchased a new position in shares of Urogen Pharma during the 3rd quarter worth $66,000. Russell Investments Group Ltd. boosted its position in shares of Urogen Pharma by 1,594.4% during the 3rd quarter. Russell Investments Group Ltd. now owns 3,321 shares of the company’s stock valued at $66,000 after acquiring an additional 3,125 shares during the last quarter. Finally, Strs Ohio acquired a new position in shares of Urogen Pharma during the 3rd quarter valued at about $76,000. Institutional investors and hedge funds own 91.29% of the company’s stock.

Urogen Pharma Price Performance

The stock has a market cap of $880.96 million, a PE ratio of -5.88 and a beta of 1.34. The stock’s fifty day moving average is $21.10 and its 200-day moving average is $20.87.

Urogen Pharma Company Profile

UroGen Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for uro-oncology and uro-genital diseases. Founded in 2010 and headquartered in Ra’anana, Israel, with offices in New York, UroGen applies its proprietary RTGel® reverse thermal gel delivery platform to create sustained-release formulations designed for in-office use by urologists.

The company’s lead product, Jelmyto® (mitomycin gel), received U.S. Food and Drug Administration approval in 2020 for the treatment of adults with low-grade upper tract urothelial cancer.